CBD and Depression: Exploring the Research

Depression is one of the most common mood disorders encountered in everyday clinical practice. Despite the increased prevalence of depressed patients, fewer than half achieve full remission, and many do not respond to antidepressant medications and/or psychotherapy.¹ This prompts patients to explore other therapies, including cannabis and its constituents like cannabidiol (CBD).² Emerging evidence suggests CBD may enhance mood and relieve feelings of depression, and some studies hint at potential applications in bipolar disorder, clinical depression, and treatment-resistant depression.

How Does the Body’s Endocannabinoid System (ECS) Influence Mood?

A healthy endocannabinoid system (ECS) is involved in cognitive function, motivation, emotions, sleep, and the stress response. The ECS comprises endogenous cannabinoids that interact with cannabinoid receptors CB1 and CB2.³ CB1 receptors—located mainly in the central and peripheral nervous system—modulate norepinephrine, serotonin, dopamine, γ-aminobutyric acid (GABA), and glutamate systems.^3,4 CB2 receptors are expressed mainly in leukocytes; activation affects inflammation and immune regulation.³

Mice lacking the CB1 receptor or given a CB1 antagonist exhibit depressive symptoms, whereas CB1 agonists show antidepressant effects.³ Human studies indicate CB1 dysfunction is an important factor in depressive symptom development.⁴ Notably, the CB1 antagonist rimonabant caused severe adverse effects—including depression and suicide—and was withdrawn from the market.⁵ CB2 receptors appear secondary in depression; CB2 agonists reverse depressive behavior in animal models.³

Some patients with major depressive disorder (MDD) show altered expression of ECS receptors and genetic polymorphisms—especially in treatment-resistant MDD.³ The endocannabinoid 2-arachidonylglycerol (2-AG) is significantly decreased in females with MDD,⁶ while other studies report elevated endocannabinoids in depressed and suicide victims.⁴ Overall, when the ECS is altered, it may contribute to mood disorders.

How CBD Influences Mood

CBD is the second most abundant cannabis constituent and crosses the blood–brain barrier, influencing cognition, mood, and emotions.⁷ It can indirectly influence CB1/CB2 receptors and is a partial agonist of 5-HT1A serotonin receptors, enhancing serotonin binding.^3,8 CBD may increase GABA production, calming the central nervous system.³

Preclinical and early clinical evidence shows CBD beneficially influences the hypothalamic-pituitary-adrenal (HPA) axis, neurogenesis, and neuroinflammation—processes often disrupted in depression.^3,9 In animal models, CBD acts as a fast-acting antidepressant via brain structures associated with depression.⁷ Because anxiety commonly co-occurs with depression, CBD’s anxiolytic actions are also relevant.^7,10,11 Ongoing stress and HPA-axis dysfunction contribute to mood disorders, and CBD may help alleviate stress.¹¹

CBD and Depression: Clinical Studies

Surveys indicate many depressed patients self-medicate with cannabis or CBD to alleviate symptoms; however, heavy cannabis use may be associated with depression in some reports (findings are mixed).^2,7,12–15

In regular, heavy cannabis users, daily administration of 200 mg CBD significantly decreased depressive and psychotic symptoms and blunted euphoria—likely because CBD counteracts THC at CB1 receptors.^16,17

For bipolar disorder (BD), a 12-week randomized, double-blind, placebo-controlled pilot trial (150–300 mg/day CBD; n=35) found significant decreases in MADRS scores overall, but no difference versus placebo—suggesting higher doses or larger trials are needed.¹⁸ Ongoing studies are evaluating higher-dose CBD in treatment-resistant BD.^19,20

What About Dosing?

Survey data suggest most people dose CBD below 50 mg/day, with ~17% exceeding 100 mg/day. Clinical studies demonstrate safety and tolerability at doses up to 6000 mg, with common side effects including GI symptoms, somnolence, and loss of appetite; CBD is not addictive.⁷

Drug interactions: Use caution with antidepressants. CBD inhibits CYP3A4 and CYP2D6, which metabolize many medications; co-administration may increase serum drug levels and side-effect risk.²¹

CBD and Mood Support: A Safer Consideration

Preclinical and early clinical studies suggest CBD may influence mood regulation, neuroinflammatory pathways, and the stress response. Larger, more rigorous clinical trials are needed to clarify its role in treating depression. Given the challenges of treatment-resistant mood disorders, clinicians may consider CBD as a potentially safer adjunct within a comprehensive care plan.

References

1. Han MH, Nestler EJ. Neural Substrates of Depression and Resilience. Neurotherapeutics. 2017;14(3):677-686.
2. Wieckiewicz G et al. Cannabidiol (CBD) in the Self-Treatment of Depression—Exploratory Study. Front Psychiatry. 2022;13:837946.
3. Zarazúa-Guzmán S et al. Endocannabinoid system as a potential target for therapy. Basic Clin Pharmacol Toxicol. 2024;135(6):669-684.
4. Smaga I et al. The endocannabinoid/endovanilloid system and depression. Curr Neuropharmacol. 2014;12(5):462-474.
5. Bright U, Akirav I. Modulation of ECS components in depression. Int J Mol Sci. 2022;23(10).
6. Hill MN et al. Serum endocannabinoids in females with depressive disorders. Pharmacopsychiatry. 2008;41(2):48-53.
7. Binkowska AA et al. Cannabidiol usage, efficacy, and side effects. Front Psychiatry. 2024;15:1356009.
8. Russo EB et al. Agonistic properties of cannabidiol at 5-HT1A receptors. Neurochem Res. 2005;30(8):1037-1043.
9. Gallego-Landin I et al. ECS in the pathophysiology of depression. Front Pharmacol. 2021;12:762738.
10. Kalin NH. The Critical Relationship Between Anxiety and Depression. Am J Psychiatry. 2020;177(5):365-367.
11. Crippa JA et al. Translational investigation of CBD. Front Immunol. 2018;9:2009.
12. Li X et al. Cannabis flower for immediate relief from depression. Yale J Biol Med. 2020;93(2):251-264.
13. Feingold D, Weinstein A. Cannabis and Depression. Adv Exp Med Biol. 2021;1264:67-80.
14. Jefsen OH et al. Cannabis Use Disorder and subsequent depression/bipolar risk. JAMA Psychiatry. 2023;80(8):803-810.
15. Churchill V et al. Cannabis and depression: updated meta-analysis. Psychol Med. 2025;55:e44.
16. Beale C et al. Prolonged CBD and hippocampal subfields in cannabis users. Cannabis Cannabinoid Res. 2018;3(1):94-107.
17. Solowij N et al. Prolonged CBD: psychological and cognitive effects. Cannabis Cannabinoid Res. 2018;3(1):21-34.
18. Pinto JV et al. CBD as adjunctive treatment for acute bipolar depression: Pilot. Can J Psychiatry. 2024;69(4):242-251.
19. Walji N. CBD Adjunctive Therapy for Acute Bipolar Depression. ClinicalTrials.gov: NCT05867849 (2025).
20. Smith R. CBD for Anxiety and Depression in Bipolar Disorder. ClinicalTrials.gov: NCT05457465 (2025).
21. Skelley JW et al. Use of cannabidiol in anxiety and related disorders. J Am Pharm Assoc. 2020;60(1):253-261.